Form 4: Vir Biotechnology CEO Acquires Shares and Options, Sells Shares for Tax Obligations

Marianne De Backer, CEO of Vir Biotechnology, acquired shares and options while selling shares to cover tax obligations related to vesting restricted stock units.

Summary

• Marianne De Backer, the CEO of Vir Biotechnology, filed a Form 4 detailing changes in her beneficial ownership of the company's stock.
• On February 22, 2025, she acquired 240,000 shares of common stock through restricted stock units and was granted options to purchase 480,000 shares.
• On February 24, 2025, she sold 16,122 shares at $9.4534 per share to cover tax obligations related to the vesting of restricted stock units.
• Following these transactions, De Backer directly owns 849,217 shares and indirectly owns 53,118 shares through the Ureel-De Backer Family Trust.
• She also directly owns options to purchase 480,000 shares, which vest over time starting February 22, 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The CEO is acquiring shares and options, which is positive, but also selling shares to cover taxes, which is a routine transaction. Overall, it doesn't strongly indicate positive or negative sentiment.

Positives

• The CEO's acquisition of shares and options could be seen as a positive signal, indicating confidence in the company's future prospects.

Negatives

• The sale of shares to cover tax obligations, while routine, could be perceived negatively by some investors if they interpret it as a lack of confidence.

Risks

• The vesting schedule of the options means that the CEO's incentives are aligned with the long-term performance of the company.
• However, any significant decline in the company's stock price could impact the value of these options and potentially affect the CEO's motivation.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the options suggests a long-term commitment from the CEO.

Industry Context

Insider transactions are common in the biotechnology industry, where stock options and restricted stock units are frequently used as compensation to align management's interests with those of shareholders. Monitoring these transactions can provide insights into management's sentiment about the company's prospects.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
• Companies like Regeneron, Gilead, and Amgen also utilize stock options and restricted stock units to incentivize their executives.
• The vesting schedule of the options is typical for the industry, with a four-year vesting period being common.

Stakeholder Impact

• The transactions could have a minor impact on shareholders, depending on how they interpret the CEO's actions.
• Employees may view the CEO's stock ownership as a sign of commitment to the company's success.

Key Dates